Dossier assessment
Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with treatment-naive advanced renal cell carcinoma
Added benefit not proven.
Additional information
Federal Joint Committee (G-BA)
2021-10-21 A G-BA decision was published.
Project details
- Project no.
- A21-49
- Commission
- Commission awarded on 29.04.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2021-08-02.
Connected Projects
-
Dossier assessment
Cabozantinib (thyroid carcinoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)
Status: Commission completed
-
Addendum
Cabozantinib (renal cell carcinoma) - Addendum to Commission A21-49
Status: Commission completed
-
Addendum
Cabozantinib (renal cell carcinoma) - Addendum to Commission A21-49
Status: Commission completed
-
Dossier assessment
Cabozantinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed